Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled Phase 3 Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions

NCT07431502 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT07431502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled Phase 3 Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
November 30, 2030
Enrollment
984 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with primary hpv high-grade squamous intra-epithelial lesions (hsil) at anal site, patients with primary hpv high-grade squamous intra-epithelial lesions (hsil) at cervical site, patients with primary hpv high-grade squamous intra-epithelial lesions (hsil) at penile site, patients with primary hpv high-grade squamous intra-epithelial lesions (hsil) at vaginal site, patients with primary hpv high-grade squamous intra-epithelial lesions (hsil) at vulvar site